[SCHEDULE 13G/A] Outlook Therapeutics, Inc. SEC Filing
Outlook Therapeutics, Inc. Schedule 13G/A reports that Tang Capital entities and Kevin Tang collectively beneficially own 1,500,000 shares of the company's common stock, representing 3.4% of the outstanding class on a diluted basis. Those shares are currently issuable upon exercise of warrants held by Tang Capital Partners, LP, and the filing states the percentages are based on 43,692,728 shares (42,192,728 outstanding plus 1,500,000 issuable warrants). TCP's warrants are exercisable for one share each but include a beneficial ownership cap preventing exercise that would increase ownership above 9.99% unless TCP provides notice to increase to a maximum of 19.99% with a 61-day delay. Voting and dispositive power over the shares is shared among Tang Capital Management, Tang Capital Partners, LP and Kevin Tang.
Outlook Therapeutics, Inc. Nel modulo Schedule 13G/A si comunica che entit脿 collegate a Tang Capital e Kevin Tang possiedono collettivamente la titolarit脿 beneficiaria di 1.500.000 azioni ordinarie della societ脿, pari a 3,4% dell'azione in circolazione su base diluita. Le azioni sono attualmente emesse in conseguenza dell'esercizio di warrant detenuti da Tang Capital Partners, LP, e il deposito indica che le percentuali si basano su 43.692.728 azioni (42.192.728 in circolazione pi霉 1.500.000 warrant esercitabili). I warrant di TCP danno diritto a una azione ciascuno ma includono un tetto di partecipazione che impedisce l'esercizio qualora l'operazione aumenti la partecipazione oltre il 9,99%, salvo che TCP dia notifica per aumentare il limite fino a un massimo del 19,99% con un ritardo di 61 giorni. Il potere di voto e di disposizione sulle azioni 猫 condiviso tra Tang Capital Management, Tang Capital Partners, LP e Kevin Tang.
Outlook Therapeutics, Inc. El informe Schedule 13G/A indica que entidades vinculadas a Tang Capital y Kevin Tang poseen colectivamente la titularidad beneficiaria de 1.500.000 acciones ordinarias de la compa帽铆a, lo que representa el 3,4% de la clase en circulaci贸n en base diluida. Esas acciones son actualmente emitibles al ejercer warrants en poder de Tang Capital Partners, LP, y la presentaci贸n se帽ala que los porcentajes se calculan sobre 43.692.728 acciones (42.192.728 en circulaci贸n m谩s 1.500.000 warrants emitibles). Los warrants de TCP son ejercitables por una acci贸n cada uno pero incluyen un l铆mite de participaci贸n que impide el ejercicio si ello incrementar铆a la participaci贸n por encima del 9,99%, salvo que TCP notifique para aumentarlo hasta un m谩ximo del 19,99% con un retraso de 61 d铆as. El poder de voto y de disposici贸n sobre las acciones se comparte entre Tang Capital Management, Tang Capital Partners, LP y Kevin Tang.
Outlook Therapeutics, Inc. 鞝滌稖霅� Schedule 13G/A鞐� 霐半ゴ氅� Tang Capital 瓿勳棿靷摛瓿� Kevin Tang鞚� 瓿惦彊鞙茧 須岇偓 氤错喌欤� 1,500,000欤检棎 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 頋劃 旮办 氚滍枆欤检嫕鞚� 3.4%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 欤检嫕鞚� 順勳灛 Tang Capital Partners, LP臧� 氤挫湢頃� 鞗岆煱韸� 頄夓偓搿� 氚滍枆 臧�電ロ暅 欤检嫕鞚措┌, 鞝滌稖靹滊電� 牍勳湪鞚� 43,692,728欤�(鞙犿喌欤� 42,192,728欤� + 頄夓偓臧�電� 鞗岆煱韸� 1,500,000欤�)毳� 旮办鞙茧 靷办爼霅橃棃雼り碃 氚濏灆雼堧嫟. TCP鞚� 鞗岆煱韸鸽姅 臧侁皝 1欤茧ゼ 旆摑頃� 靾� 鞛堨溂雮�, 靻岇湢歆�攵勳澊 9.99%毳� 齑堦臣頃橁矊 霅橂姅 瓴届毎 頄夓偓毳� 鞝滍暅頃橂姅 靻岇湢 頃滊弰臧� 韽暔霅橃柎 鞛堦碃, TCP臧� 韱奠頃橂┐ 斓滊寑 19.99%旯岇 歃濌皜鞁滍偓 靾� 鞛堨溂雮� 61鞚检潣 歆�鞐� 旮瓣皠鞚� 鞝侅毄霅╇媹雼�. 頃措嫻 欤检嫕鞐� 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇潃 Tang Capital Management, Tang Capital Partners, LP 氚� Kevin Tang 臧勳棎 瓿奠湢霅╇媹雼�.
Outlook Therapeutics, Inc. Le Schedule 13G/A indique que des entit茅s li茅es 脿 Tang Capital et Kevin Tang d茅tiennent collectivement la propri茅t茅 b茅n茅ficiaire de 1 500 000 actions ordinaires de la soci茅t茅, repr茅sentant 3,4% de la classe en circulation sur une base dilu茅e. Ces actions sont actuellement susceptibles d'锚tre 茅mises 脿 l'exercice de warrants d茅tenus par Tang Capital Partners, LP, et le d茅p么t pr茅cise que les pourcentages sont calcul茅s sur 43 692 728 actions (42 192 728 en circulation plus 1 500 000 warrants exer莽ables). Les warrants de TCP donnent droit 脿 une action chacun mais comportent un plafond de participation emp锚chant l'exercice si cela portait la participation au-del脿 de 9,99%, sauf si TCP notifie une augmentation jusqu'脿 un maximum de 19,99% avec un d茅lai de 61 jours. Le pouvoir de vote et de disposition sur les actions est partag茅 entre Tang Capital Management, Tang Capital Partners, LP et Kevin Tang.
Outlook Therapeutics, Inc. Im Formular Schedule 13G/A wird berichtet, dass von Tang Capital nahestehende Einheiten und Kevin Tang zusammen wirtschaftlich 1.500.000 Stammaktien der Gesellschaft halten, was 3,4% der ausstehenden Klasse auf verw盲sserter Basis entspricht. Diese Aktien sind derzeit aus der Aus眉bung von Warrants entstanden, die Tang Capital Partners, LP h盲lt; die Meldung gibt an, dass sich die Prozents盲tze auf 43.692.728 Aktien (42.192.728 ausstehend plus 1.500.000 aus眉bungsf盲hige Warrants) beziehen. Die Warrants von TCP berechtigen jeweils zum Erwerb einer Aktie, enthalten jedoch eine Besitzobergrenze, die eine Aus眉bung verhindert, wenn dadurch der Anteil 眉ber 9,99% steigen w眉rde, es sei denn, TCP gibt eine Mitteilung zur Erh枚hung bis maximal 19,99% mit einer Verz枚gerung von 61 Tagen. Stimm- und Verf眉gungsmacht 眉ber die Aktien wird zwischen Tang Capital Management, Tang Capital Partners, LP und Kevin Tang geteilt.
- Clear disclosure of beneficial ownership and exercise mechanics for 1,500,000 warrants (transparency for investors)
- Exercise cap (9.99% default) limits immediate concentration of ownership, reducing near-term takeover/control risk
- Shared voting/dispositive power among related parties could enable coordinated action despite modest percentage
- Warrants are exercisable which could dilute existing shareholders if exercised (adds potential dilution of 1,500,000 shares)
Insights
TL;DR: Tang Capital reports a modest 3.4% warrant-based stake with exercise limits that constrain near-term ownership concentration.
The filing is a routine 13G/A disclosing beneficial ownership via currently exercisable warrants totaling 1,500,000 shares, calculated on a diluted share base of 43,692,728. The 9.99% beneficial ownership cap on warrant exercise (expandable to 19.99% after notice and delay) is material to control dynamics because it limits immediate accumulation. Shared voting and dispositive power among related parties indicates coordinated ownership reporting but no single-party sole control. Impact for investors is neutral; the position is modest and subject to contractual exercise constraints.
TL;DR: Related-party group disclosed coordinated control over warrants but no present intent to influence control is asserted.
The statement certifies the securities were not acquired to change or influence issuer control and identifies the filing parties and their relationships. Signatures by Kevin Tang across entities confirm centralized management of the reported position. The disclosure clarifies exercise mechanics and ownership caps, which are important governance details for monitoring potential future concentration. This is a standard disclosure without immediate governance red flags.
Outlook Therapeutics, Inc. Nel modulo Schedule 13G/A si comunica che entit脿 collegate a Tang Capital e Kevin Tang possiedono collettivamente la titolarit脿 beneficiaria di 1.500.000 azioni ordinarie della societ脿, pari a 3,4% dell'azione in circolazione su base diluita. Le azioni sono attualmente emesse in conseguenza dell'esercizio di warrant detenuti da Tang Capital Partners, LP, e il deposito indica che le percentuali si basano su 43.692.728 azioni (42.192.728 in circolazione pi霉 1.500.000 warrant esercitabili). I warrant di TCP danno diritto a una azione ciascuno ma includono un tetto di partecipazione che impedisce l'esercizio qualora l'operazione aumenti la partecipazione oltre il 9,99%, salvo che TCP dia notifica per aumentare il limite fino a un massimo del 19,99% con un ritardo di 61 giorni. Il potere di voto e di disposizione sulle azioni 猫 condiviso tra Tang Capital Management, Tang Capital Partners, LP e Kevin Tang.
Outlook Therapeutics, Inc. El informe Schedule 13G/A indica que entidades vinculadas a Tang Capital y Kevin Tang poseen colectivamente la titularidad beneficiaria de 1.500.000 acciones ordinarias de la compa帽铆a, lo que representa el 3,4% de la clase en circulaci贸n en base diluida. Esas acciones son actualmente emitibles al ejercer warrants en poder de Tang Capital Partners, LP, y la presentaci贸n se帽ala que los porcentajes se calculan sobre 43.692.728 acciones (42.192.728 en circulaci贸n m谩s 1.500.000 warrants emitibles). Los warrants de TCP son ejercitables por una acci贸n cada uno pero incluyen un l铆mite de participaci贸n que impide el ejercicio si ello incrementar铆a la participaci贸n por encima del 9,99%, salvo que TCP notifique para aumentarlo hasta un m谩ximo del 19,99% con un retraso de 61 d铆as. El poder de voto y de disposici贸n sobre las acciones se comparte entre Tang Capital Management, Tang Capital Partners, LP y Kevin Tang.
Outlook Therapeutics, Inc. 鞝滌稖霅� Schedule 13G/A鞐� 霐半ゴ氅� Tang Capital 瓿勳棿靷摛瓿� Kevin Tang鞚� 瓿惦彊鞙茧 須岇偓 氤错喌欤� 1,500,000欤检棎 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 頋劃 旮办 氚滍枆欤检嫕鞚� 3.4%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 欤检嫕鞚� 順勳灛 Tang Capital Partners, LP臧� 氤挫湢頃� 鞗岆煱韸� 頄夓偓搿� 氚滍枆 臧�電ロ暅 欤检嫕鞚措┌, 鞝滌稖靹滊電� 牍勳湪鞚� 43,692,728欤�(鞙犿喌欤� 42,192,728欤� + 頄夓偓臧�電� 鞗岆煱韸� 1,500,000欤�)毳� 旮办鞙茧 靷办爼霅橃棃雼り碃 氚濏灆雼堧嫟. TCP鞚� 鞗岆煱韸鸽姅 臧侁皝 1欤茧ゼ 旆摑頃� 靾� 鞛堨溂雮�, 靻岇湢歆�攵勳澊 9.99%毳� 齑堦臣頃橁矊 霅橂姅 瓴届毎 頄夓偓毳� 鞝滍暅頃橂姅 靻岇湢 頃滊弰臧� 韽暔霅橃柎 鞛堦碃, TCP臧� 韱奠頃橂┐ 斓滊寑 19.99%旯岇 歃濌皜鞁滍偓 靾� 鞛堨溂雮� 61鞚检潣 歆�鞐� 旮瓣皠鞚� 鞝侅毄霅╇媹雼�. 頃措嫻 欤检嫕鞐� 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇潃 Tang Capital Management, Tang Capital Partners, LP 氚� Kevin Tang 臧勳棎 瓿奠湢霅╇媹雼�.
Outlook Therapeutics, Inc. Le Schedule 13G/A indique que des entit茅s li茅es 脿 Tang Capital et Kevin Tang d茅tiennent collectivement la propri茅t茅 b茅n茅ficiaire de 1 500 000 actions ordinaires de la soci茅t茅, repr茅sentant 3,4% de la classe en circulation sur une base dilu茅e. Ces actions sont actuellement susceptibles d'锚tre 茅mises 脿 l'exercice de warrants d茅tenus par Tang Capital Partners, LP, et le d茅p么t pr茅cise que les pourcentages sont calcul茅s sur 43 692 728 actions (42 192 728 en circulation plus 1 500 000 warrants exer莽ables). Les warrants de TCP donnent droit 脿 une action chacun mais comportent un plafond de participation emp锚chant l'exercice si cela portait la participation au-del脿 de 9,99%, sauf si TCP notifie une augmentation jusqu'脿 un maximum de 19,99% avec un d茅lai de 61 jours. Le pouvoir de vote et de disposition sur les actions est partag茅 entre Tang Capital Management, Tang Capital Partners, LP et Kevin Tang.
Outlook Therapeutics, Inc. Im Formular Schedule 13G/A wird berichtet, dass von Tang Capital nahestehende Einheiten und Kevin Tang zusammen wirtschaftlich 1.500.000 Stammaktien der Gesellschaft halten, was 3,4% der ausstehenden Klasse auf verw盲sserter Basis entspricht. Diese Aktien sind derzeit aus der Aus眉bung von Warrants entstanden, die Tang Capital Partners, LP h盲lt; die Meldung gibt an, dass sich die Prozents盲tze auf 43.692.728 Aktien (42.192.728 ausstehend plus 1.500.000 aus眉bungsf盲hige Warrants) beziehen. Die Warrants von TCP berechtigen jeweils zum Erwerb einer Aktie, enthalten jedoch eine Besitzobergrenze, die eine Aus眉bung verhindert, wenn dadurch der Anteil 眉ber 9,99% steigen w眉rde, es sei denn, TCP gibt eine Mitteilung zur Erh枚hung bis maximal 19,99% mit einer Verz枚gerung von 61 Tagen. Stimm- und Verf眉gungsmacht 眉ber die Aktien wird zwischen Tang Capital Management, Tang Capital Partners, LP und Kevin Tang geteilt.
FAQ
How many shares does Tang Capital beneficially own in Outlook Therapeutics (OTLK)?
Are the reported shares currently outstanding or exercisable warrants?
Is there any limit on how many warrants TCP can exercise?
Who shares voting and dispositive power over these shares?
Does the filing state intent to influence control of the issuer?
